Howard J. Zeft, M.D.; Sandra D. Patterson, B.S.; Edward S. Orgain, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
There is increasing evidence that propranolol hydrochloride, a beta-adrenergic receptor blocking agent, may be a useful adjunct in the treatment of angina pectoris. The effect of this agent in the long-term management of 65 patients with severe ischemic (coronary) heart disease was evaluated. Fifty-seven patients received propranolol for 6 to 24 months. Sixty-five percent of the patients exhibited a sustained 50% or more reduction both in frequency of anginal pain and in nitroglycerin requirement. For a given patient there was a dose threshold, between 160 and 400 mg/day, at which maximum relief of symptoms was attained. The reduction of resting
Learn more about subscription options.
Register Now for a free account.
Zeft HJ, Patterson SD, Orgain ES. Propranolol in the Long-Term Treatment of Angina Pectoris.. Ann Intern Med. 1969;70:1082. doi: 10.7326/0003-4819-70-5-1082_1
Download citation file:
Published: Ann Intern Med. 1969;70(5):1082.
Cardiology, Coronary Heart Disease, Coronary Risk Factors, Geriatric Medicine, Hypertension.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only